Knowledge graph · Drug
Camizestrant
small molecule
- Identifier
- CI-DRUG-00000778
- Entity page
- /drug/camizestrant ↗
- Edges
- 38
- Neighbours
- 12 cancers1 genes10 trials2 approvals
- Drawn
- 25 of 25 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Camizestrant approved for …APPROVED_FOR3 of 2 | ||||||||
| → approved for | Malignant Breast Neoplasmcancer_family | supports | FDA ORIG | Malignant Breast Neoplasm | 1 | Regulatory | openfda | graph → |
| → approved for | EMA · EU · 2026Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1). | |||||||